Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma

Immune checkpoint inhibitors (ICIs) are an integral antitumor therapy for many malignancies. Most patients show very good tolerability to ICIs; however, serious immune-related adverse events (irAEs) with ICIs have been well documented and prevent some patients from continuing ICIs or even become the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Hang-Yu, Zhao, Jing-Wen, Wang, Yin-Shuang, Meng, Zhuo-Nan, Zhu, Xiu-Ming, Wang, Fu-Wei, Zheng, Ai-Hong, Wu, Guo-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409480/
https://www.ncbi.nlm.nih.gov/pubmed/37559729
http://dx.doi.org/10.3389/fimmu.2023.1148425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409480/
https://www.ncbi.nlm.nih.gov/pubmed/37559729
http://dx.doi.org/10.3389/fimmu.2023.1148425

Ejemplares similares